» Articles » PMID: 33374332

DNA Methylation in Prostate Tumor Tissue Is Associated with Gleason Score

Abstract

Increasing evidence suggests a role of epigenetic mechanisms at chromosome 8q24, an important cancer genetic susceptibility region, in prostate cancer. We investigated whether DNA methylation at 8q24 (six CpG sites from exon 3 to the 3' UTR) in prostate tumor was associated with tumor aggressiveness (based on Gleason score, GS), and we incorporated RNA expression data to investigate the function. We accessed radical prostatectomy tissue for 50 Caucasian and 50 African American prostate cancer patients at the University of Maryland Medical Center, selecting an equal number of GS 6 and GS 7 cases per group. DNA methylation was lower in tumor than paired normal prostate tissue for all six CpG sites (median difference: -14.74 to -0.20 percentage points), and we observed similar results for two nearby sites in The Cancer Genome Atlas ( < 0.0001). We observed significantly lower methylation for more aggressive (GS 7) than less aggressive (GS 6) tumors for three exon 3 sites (for CpG 212 (chr8:128753145), GS 6 median = 89.7%; GS 7 median = 85.8%; -value = 9.4 × 10). DNA methylation was not associated with expression, but was inversely associated with expression after multiple comparison adjustment (-value = 0.04). Findings suggest that prostate tumor exon 3 hypomethylation is associated with increased aggressiveness.

Citing Articles

The Diagnostic Yield of Investigating Developmental Regression in Children: A Systematic Review and Meta-Analysis.

Furley K, Teo A, Williams K, Alshawsh M, Brignell A J Autism Dev Disord. 2025; .

PMID: 39976758 DOI: 10.1007/s10803-025-06749-4.


Neighborhood Disadvantage and Prostate Tumor RNA Expression of Stress-Related Genes.

Boyle J, Yau J, Slade J, Butts D, Zhang Y, Legesse T JAMA Netw Open. 2024; 7(7):e2421903.

PMID: 38995644 PMC: 11245728. DOI: 10.1001/jamanetworkopen.2024.21903.


Firefighting, per- and polyfluoroalkyl substances, and DNA methylation of genes associated with prostate cancer risk.

Quaid M, Goodrich J, Calkins M, Graber J, Urwin D, Gabriel J Environ Mol Mutagen. 2024; 65(1-2):55-66.

PMID: 38523457 PMC: 11006564. DOI: 10.1002/em.22589.


Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients.

Stevens C, Hightower A, Buxbaum S, Falzarano S, Rhie S Front Oncol. 2023; 13:1079037.

PMID: 36937425 PMC: 10018228. DOI: 10.3389/fonc.2023.1079037.


Epigenetics in prostate cancer treatment.

Jones K, Zhang Y, Kong Y, Farah E, Wang R, Li C J Transl Genet Genom. 2022; 5:341-356.

PMID: 35372800 PMC: 8974353. DOI: 10.20517/jtgg.2021.19.


References
1.
Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

2.
Kirby M, Ramaker R, Roberts B, Lasseigne B, Gunther D, Burwell T . Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns. BMC Cancer. 2017; 17(1):273. PMC: 5392915. DOI: 10.1186/s12885-017-3252-2. View

3.
Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

4.
Barry K, Moore L, Liao L, Huang W, Andreotti G, Poulin M . Prospective study of DNA methylation at LINE-1 and Alu in peripheral blood and the risk of prostate cancer. Prostate. 2015; 75(15):1718-25. PMC: 4535169. DOI: 10.1002/pros.23053. View

5.
Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A . Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One. 2009; 4(3):e4830. PMC: 2653233. DOI: 10.1371/journal.pone.0004830. View